Literature DB >> 24481602

Altered expression and function of canalicular transporters during early development of cholestatic liver injury in Abcb4-deficient mice.

Shi-Ying Cai1, Albert Mennone, Carol J Soroka, James L Boyer.   

Abstract

Deficiency of ABCB4 is associated with several forms of cholestasis in humans. Abcb4(-/-) mice also develop cholestasis, but it remains uncertain what role other canalicular transporters play in the development of this disease. We examined the expression of these transporters in Abcb4(-/-) mice compared with their wild-type littermate controls at ages of 10 days and 3, 6, and 12 wk. Elevated plasma bile acid levels were already detected at 10 days and at all ages thereafter in Abcb4(-/-) mice. The expression of Bsep, Mrp2, Atp8b1, Abcg5, and Abcg8 liver proteins did not change at 10 days, but Bsep, Mrp2, and Atp8b1 were reduced, whereas Abcg5 and Abcg8 expression were increased in Abcb4(-/-) mice at all later ages. Lower bile acid concentrations were also detected in the bile of 6-wk-old Abcb4(-/-) mice. Immunofluorescence labeling revealed distorted canalicular architecture in the liver tissue by 12 wk in Abcb4(-/-) mice. Whereas Bsep and Mrp2 remained associated with the apical membrane, Atp8b1 was now localized in discrete punctuate structures adjacent to the canalicular membrane in these mice. Expression of Bsep mRNA was increased in the livers of 10-day-old Abcb4(-/-) mice, whereas Ost-α was decreased. By 12 wk, Bsep, Mrp2, and Abcg5 mRNA were all increased, whereas Ost-α and Ntcp were reduced. These findings indicate that canalicular transporters that determine the formation of bile are altered early in the development of cholestasis in Abcb4(-/-) mice and may contribute to the pathogenesis of cholestasis in this disorder.

Entities:  

Keywords:  Abcb4; bile; canalicular transporter; cholestasis; phospholipid

Mesh:

Substances:

Year:  2014        PMID: 24481602      PMCID: PMC3989703          DOI: 10.1152/ajpgi.00334.2013

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  25 in total

1.  The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood.

Authors:  E Jacquemin; J M De Vree; D Cresteil; E M Sokal; E Sturm; M Dumont; G L Scheffer; M Paul; M Burdelski; P J Bosma; O Bernard; M Hadchouel; R P Elferink
Journal:  Gastroenterology       Date:  2001-05       Impact factor: 22.682

2.  Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis.

Authors:  J M de Vree; E Jacquemin; E Sturm; D Cresteil; P J Bosma; J Aten; J F Deleuze; M Desrochers; M Burdelski; O Bernard; R P Oude Elferink; M Hadchouel
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

3.  Effect of mdr2 mutation with combined tandem disruption of canalicular glycoprotein transporters by cyclosporine A on bile formation in mice.

Authors:  Abdelkader Elamiri; Shahid Perwaiz; Beatriz Tuchweber; Ibrahim M Yousef
Journal:  Pharmacol Res       Date:  2003-11       Impact factor: 7.658

4.  Multiple inflammatory-, tissue remodelling- and fibrosis genes are differentially transcribed in the livers of Abcb4 (-/ - ) mice harbouring chronic cholangitis.

Authors:  Karl Esten Nakken; Ståle Nygård; Terese Haaland; Knut Erik Berge; Kristin Arnkvaern; Annlaug Ødegaard; Knut Jørgen Labori; Morten G Raeder
Journal:  Scand J Gastroenterol       Date:  2007-10       Impact factor: 2.423

Review 5.  Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics.

Authors:  A F Hofmann; L R Hagey
Journal:  Cell Mol Life Sci       Date:  2008-08       Impact factor: 9.261

6.  Regulation of biliary lipid secretion by mdr2 P-glycoprotein in the mouse.

Authors:  R P Oude Elferink; R Ottenhoff; M van Wijland; J J Smit; A H Schinkel; A K Groen
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

Review 7.  Biliary lipids and cholesterol gallstone disease.

Authors:  David Q-H Wang; David E Cohen; Martin C Carey
Journal:  J Lipid Res       Date:  2008-11-17       Impact factor: 5.922

8.  The human MDR3 P-glycoprotein promotes translocation of phosphatidylcholine through the plasma membrane of fibroblasts from transgenic mice.

Authors:  A J Smith; J L Timmermans-Hereijgers; B Roelofsen; K W Wirtz; W J van Blitterswijk; J J Smit; A H Schinkel; P Borst
Journal:  FEBS Lett       Date:  1994-11-14       Impact factor: 4.124

9.  Complementary functions of the flippase ATP8B1 and the floppase ABCB4 in maintaining canalicular membrane integrity.

Authors:  Annemiek Groen; Marta Rodriguez Romero; Cindy Kunne; Sarah J Hoosdally; Peter H Dixon; Carol Wooding; Catherine Williamson; Jurgen Seppen; Karin Van den Oever; Kam S Mok; Coen C Paulusma; Kenneth J Linton; Ronald P J Oude Elferink
Journal:  Gastroenterology       Date:  2011-08-04       Impact factor: 22.682

10.  Retinoic acid represses CYP7A1 expression in human hepatocytes and HepG2 cells by FXR/RXR-dependent and independent mechanisms.

Authors:  Shi-Ying Cai; Hongwei He; Trong Nguyen; Albert Mennone; James L Boyer
Journal:  J Lipid Res       Date:  2010-03-25       Impact factor: 5.922

View more
  10 in total

1.  Mouse models of liver fibrosis mimic human liver fibrosis of different etiologies.

Authors:  Allyson K Martínez; Luca Maroni; Marco Marzioni; Syed T Ahmed; Mena Milad; Debolina Ray; Gianfranco Alpini; Shannon S Glaser
Journal:  Curr Pathobiol Rep       Date:  2014-12-01

Review 2.  Therapeutic targets for cholestatic liver injury.

Authors:  Benjamin L Woolbright; Hartmut Jaeschke
Journal:  Expert Opin Ther Targets       Date:  2015-10-19       Impact factor: 6.902

3.  Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response.

Authors:  Shi-Ying Cai; Xinshou Ouyang; Yonglin Chen; Carol J Soroka; Juxian Wang; Albert Mennone; Yucheng Wang; Wajahat Z Mehal; Dhanpat Jain; James L Boyer
Journal:  JCI Insight       Date:  2017-03-09

Review 4.  Fibrates and cholestasis.

Authors:  Nisanne S Ghonem; David N Assis; James L Boyer
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

5.  Interleukin 2 Promotes Hepatic Regulatory T Cell Responses and Protects From Biliary Fibrosis in Murine Sclerosing Cholangitis.

Authors:  Amy E Taylor; Alexandra N Carey; Ramesh Kudira; Celine S Lages; Tiffany Shi; Simon Lam; Rebekah Karns; Julia Simmons; Kumar Shanmukhappa; Maha Almanan; Claire A Chougnet; Alexander G Miethke
Journal:  Hepatology       Date:  2018-09-30       Impact factor: 17.425

6.  Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis.

Authors:  Shi-Ying Cai; Dongke Yu; Carol J Soroka; Jing Wang; James L Boyer
Journal:  J Hepatol       Date:  2020-10-09       Impact factor: 25.083

7.  Huangqi Decoction Alleviates Alpha-Naphthylisothiocyanate Induced Intrahepatic Cholestasis by Reversing Disordered Bile Acid and Glutathione Homeostasis in Mice.

Authors:  Jia-Sheng Wu; Yi-Fei Li; Yuan-Yuan Li; Yan Dai; Wen-Kai Li; Min Zheng; Zheng-Chun Shi; Rong Shi; Tian-Ming Wang; Bing-Liang Ma; Ping Liu; Yue-Ming Ma
Journal:  Front Pharmacol       Date:  2017-12-21       Impact factor: 5.810

8.  Studies on the mechanisms of bile acid initiated hepatic inflammation in cholestatic liver injury.

Authors:  Shi-Ying Cai; James L Boyer
Journal:  Inflamm Cell Signal       Date:  2017-06-19

9.  H19 Is Expressed in Hybrid Hepatocyte Nuclear Factor 4α+ Periportal Hepatocytes but Not Cytokeratin 19+ Cholangiocytes in Cholestatic Livers.

Authors:  YanChao Jiang; Yi Huang; ShiYing Cai; YongFeng Song; James L Boyer; KeZhong Zhang; Ling Gao; JiaJun Zhao; WenDong Huang; Guang Liang; Suthat Liangpunsakul; Li Wang
Journal:  Hepatol Commun       Date:  2018-09-24

10.  Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice.

Authors:  Mei Zhou; R Marc Learned; Stephen J Rossi; Alex M DePaoli; Hui Tian; Lei Ling
Journal:  Hepatology       Date:  2015-11-30       Impact factor: 17.425

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.